Genetic modification immunotherapy for blood cancer is a technique that involves genetic modification of immune system T cells.It allows T cells to recognize weakly expressed antigens in the blood or other organs of the body, such as tumor cells.This form of immunotherapy can be divided into two types: one in which the patient receives genetically modified immune cells from a donor, and the other in which the patient's own immune cells are removed, genetically modified and then given back to the patient.CAR T cell therapy involves genetically altering immune system T cells to produce a protein called CAR or chimeric antigen receptor protein, which helps T cells attach to specific proteins on the surface of tumor cells, making it easier for them to recognize cancer cells.
Market Analysis and Insights: Global Gene Modifying Immunotherapy for Blood Cancer Market
The global Gene Modifying Immunotherapy for Blood Cancer market size is projected to reach US$ million by 2026, from US$ million in 2020, at a CAGR of % during 2021-2026.
Global Gene Modifying Immunotherapy for Blood Cancer Scope and Segment
The global Gene Modifying Immunotherapy for Blood Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gene Modifying Immunotherapy for Blood Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
By the type, the market is primarily split into
CAR T-cell Therapy
TCR T-cell Therapy
By the application, this report covers the following segments
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
B Cell Lymphoma
Multiple Myeloma
Other
Competitive Landscape:
The Gene Modifying Immunotherapy for Blood Cancer key manufacturers in this market include:
Novartis
Kite Pharma
Juno Therapeutics
Cellectis
Ziopharm Oncology
Celyad
Bluebird Bio
Bellicum Pharmaceuticals
Mustang Bio
1 Market Overview of Gene Modifying Immunotherapy for Blood Cancer
1.1 Gene Modifying Immunotherapy for Blood Cancer Market Overview
1.1.1 Gene Modifying Immunotherapy for Blood Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2015-2026)
1.4 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2015-2020)
1.5 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.5 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
2 Gene Modifying Immunotherapy for Blood Cancer Market Overview by Type
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2015-2020)
2.3 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2021-2026)
2.4 CAR T-cell Therapy
2.5 TCR T-cell Therapy
3 Gene Modifying Immunotherapy for Blood Cancer Market Overview by Application
3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2015-2020)
3.3 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2021-2026)
3.4 Acute Lymphocytic Leukemia
3.5 Chronic Lymphocytic Leukemia
3.6 B Cell Lymphoma
3.7 Multiple Myeloma
3.8 Other
4 Global Gene Modifying Immunotherapy for Blood Cancer Competition Analysis by Players
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2019)
4.3 Date of Key Manufacturers Enter into Gene Modifying Immunotherapy for Blood Cancer Market
4.4 Global Top Players Gene Modifying Immunotherapy for Blood Cancer Headquarters and Area Served
4.5 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Modifying Immunotherapy for Blood Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business and Company’s Total Revenue
5.1.3 Novartis Products, Services and Solutions
5.1.4 Novartis Revenue (US$ Million) (2015-2020)
5.1.5 Novartis Recent Development and Reaction to Covid-19
5.2 Kite Pharma
5.2.1 Kite Pharma Profile
5.2.2 Kite Pharma Main Business and Company’s Total Revenue
5.2.3 Kite Pharma Products, Services and Solutions
5.2.4 Kite Pharma Revenue (US$ Million) (2015-2020)
5.2.5 Kite Pharma Recent Development and Reaction to Covid-19
5.3 Juno Therapeutics
5.5.1 Juno Therapeutics Profile
5.3.2 Juno Therapeutics Main Business and Company’s Total Revenue
5.3.3 Juno Therapeutics Products, Services and Solutions
5.3.4 Juno Therapeutics Revenue (US$ Million) (2015-2020)
5.3.5 Cellectis Recent Development and Reaction to Covid-19
5.4 Cellectis
5.4.1 Cellectis Profile
5.4.2 Cellectis Main Business and Company’s Total Revenue
5.4.3 Cellectis Products, Services and Solutions
5.4.4 Cellectis Revenue (US$ Million) (2015-2020)
5.4.5 Cellectis Recent Development and Reaction to Covid-19
5.5 Ziopharm Oncology
5.5.1 Ziopharm Oncology Profile
5.5.2 Ziopharm Oncology Main Business and Company’s Total Revenue
5.5.3 Ziopharm Oncology Products, Services and Solutions
5.5.4 Ziopharm Oncology Revenue (US$ Million) (2015-2020)
5.5.5 Ziopharm Oncology Recent Development and Reaction to Covid-19
5.6 Celyad
5.6.1 Celyad Profile
5.6.2 Celyad Main Business and Company’s Total Revenue
5.6.3 Celyad Products, Services and Solutions
5.6.4 Celyad Revenue (US$ Million) (2015-2020)
5.6.5 Celyad Recent Development and Reaction to Covid-19
5.7 Bluebird Bio
5.7.1 Bluebird Bio Profile
5.7.2 Bluebird Bio Main Business and Company’s Total Revenue
5.7.3 Bluebird Bio Products, Services and Solutions
5.7.4 Bluebird Bio Revenue (US$ Million) (2015-2020)
5.7.5 Bluebird Bio Recent Development and Reaction to Covid-19
5.8 Bellicum Pharmaceuticals
5.8.1 Bellicum Pharmaceuticals Profile
5.8.2 Bellicum Pharmaceuticals Main Business and Company’s Total Revenue
5.8.3 Bellicum Pharmaceuticals Products, Services and Solutions
5.8.4 Bellicum Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.8.5 Bellicum Pharmaceuticals Recent Development and Reaction to Covid-19
5.9 Mustang Bio
5.9.1 Mustang Bio Profile
5.9.2 Mustang Bio Main Business and Company’s Total Revenue
5.9.3 Mustang Bio Products, Services and Solutions
5.9.4 Mustang Bio Revenue (US$ Million) (2015-2020)
5.9.5 Mustang Bio Recent Development and Reaction to Covid-19
6 North America Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
7 Europe Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
8 China Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
8.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
8.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
9 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
9.1 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
10 Latin America Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
10.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
10.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
11 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
11.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
12 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
1.1 Gene Modifying Immunotherapy for Blood Cancer Market Overview
1.1.1 Gene Modifying Immunotherapy for Blood Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Region (2015-2026)
1.4 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Region (2015-2020)
1.5 Global Gene Modifying Immunotherapy for Blood Cancer Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.3 China Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.5 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size YoY Growth (2015-2026)
2 Gene Modifying Immunotherapy for Blood Cancer Market Overview by Type
2.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Type (2015-2020)
2.3 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Type (2021-2026)
2.4 CAR T-cell Therapy
2.5 TCR T-cell Therapy
3 Gene Modifying Immunotherapy for Blood Cancer Market Overview by Application
3.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Gene Modifying Immunotherapy for Blood Cancer Historic Market Size by Application (2015-2020)
3.3 Global Gene Modifying Immunotherapy for Blood Cancer Forecasted Market Size by Application (2021-2026)
3.4 Acute Lymphocytic Leukemia
3.5 Chronic Lymphocytic Leukemia
3.6 B Cell Lymphoma
3.7 Multiple Myeloma
3.8 Other
4 Global Gene Modifying Immunotherapy for Blood Cancer Competition Analysis by Players
4.1 Global Gene Modifying Immunotherapy for Blood Cancer Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Modifying Immunotherapy for Blood Cancer as of 2019)
4.3 Date of Key Manufacturers Enter into Gene Modifying Immunotherapy for Blood Cancer Market
4.4 Global Top Players Gene Modifying Immunotherapy for Blood Cancer Headquarters and Area Served
4.5 Key Players Gene Modifying Immunotherapy for Blood Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Gene Modifying Immunotherapy for Blood Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business and Company’s Total Revenue
5.1.3 Novartis Products, Services and Solutions
5.1.4 Novartis Revenue (US$ Million) (2015-2020)
5.1.5 Novartis Recent Development and Reaction to Covid-19
5.2 Kite Pharma
5.2.1 Kite Pharma Profile
5.2.2 Kite Pharma Main Business and Company’s Total Revenue
5.2.3 Kite Pharma Products, Services and Solutions
5.2.4 Kite Pharma Revenue (US$ Million) (2015-2020)
5.2.5 Kite Pharma Recent Development and Reaction to Covid-19
5.3 Juno Therapeutics
5.5.1 Juno Therapeutics Profile
5.3.2 Juno Therapeutics Main Business and Company’s Total Revenue
5.3.3 Juno Therapeutics Products, Services and Solutions
5.3.4 Juno Therapeutics Revenue (US$ Million) (2015-2020)
5.3.5 Cellectis Recent Development and Reaction to Covid-19
5.4 Cellectis
5.4.1 Cellectis Profile
5.4.2 Cellectis Main Business and Company’s Total Revenue
5.4.3 Cellectis Products, Services and Solutions
5.4.4 Cellectis Revenue (US$ Million) (2015-2020)
5.4.5 Cellectis Recent Development and Reaction to Covid-19
5.5 Ziopharm Oncology
5.5.1 Ziopharm Oncology Profile
5.5.2 Ziopharm Oncology Main Business and Company’s Total Revenue
5.5.3 Ziopharm Oncology Products, Services and Solutions
5.5.4 Ziopharm Oncology Revenue (US$ Million) (2015-2020)
5.5.5 Ziopharm Oncology Recent Development and Reaction to Covid-19
5.6 Celyad
5.6.1 Celyad Profile
5.6.2 Celyad Main Business and Company’s Total Revenue
5.6.3 Celyad Products, Services and Solutions
5.6.4 Celyad Revenue (US$ Million) (2015-2020)
5.6.5 Celyad Recent Development and Reaction to Covid-19
5.7 Bluebird Bio
5.7.1 Bluebird Bio Profile
5.7.2 Bluebird Bio Main Business and Company’s Total Revenue
5.7.3 Bluebird Bio Products, Services and Solutions
5.7.4 Bluebird Bio Revenue (US$ Million) (2015-2020)
5.7.5 Bluebird Bio Recent Development and Reaction to Covid-19
5.8 Bellicum Pharmaceuticals
5.8.1 Bellicum Pharmaceuticals Profile
5.8.2 Bellicum Pharmaceuticals Main Business and Company’s Total Revenue
5.8.3 Bellicum Pharmaceuticals Products, Services and Solutions
5.8.4 Bellicum Pharmaceuticals Revenue (US$ Million) (2015-2020)
5.8.5 Bellicum Pharmaceuticals Recent Development and Reaction to Covid-19
5.9 Mustang Bio
5.9.1 Mustang Bio Profile
5.9.2 Mustang Bio Main Business and Company’s Total Revenue
5.9.3 Mustang Bio Products, Services and Solutions
5.9.4 Mustang Bio Revenue (US$ Million) (2015-2020)
5.9.5 Mustang Bio Recent Development and Reaction to Covid-19
6 North America Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
6.1 North America Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
6.2 North America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
7 Europe Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
7.1 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
7.2 Europe Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
8 China Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
8.1 China Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
8.2 China Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
9 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
9.1 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
10 Latin America Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
10.1 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
10.2 Latin America Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
11 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer by Players and by Application
11.1 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Gene Modifying Immunotherapy for Blood Cancer Market Size by Application (2015-2020)
12 Gene Modifying Immunotherapy for Blood Cancer Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis
13 Research Finding /Conclusion
14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
